Autolus Therapeutics (NASDAQ:AUTL) Upgraded at Redburn Atlantic

Redburn Atlantic upgraded shares of Autolus Therapeutics (NASDAQ:AUTL) from a neutral rating to a buy rating in a report published on Friday morning, Marketbeat.com reports. The firm currently has $13.00 price target on the stock.

Separately, Needham & Company LLC restated a “buy” rating and issued a $9.00 target price on shares of Autolus Therapeutics in a research note on Monday, November 11th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $9.45.

Autolus Therapeutics Stock Up 2.3 %

Shares of NASDAQ:AUTL opened at $3.08 on Friday. The firm has a market cap of $819.56 million, a price-to-earnings ratio of -2.55 and a beta of 2.04. Autolus Therapeutics has a 12 month low of $2.94 and a 12 month high of $7.45. The company’s fifty day simple moving average is $3.91 and its 200 day simple moving average is $3.99.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter in the previous year, the business earned ($0.26) earnings per share. Research analysts expect that Autolus Therapeutics will post -0.94 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

Several hedge funds have recently modified their holdings of AUTL. Exchange Traded Concepts LLC boosted its position in Autolus Therapeutics by 9.8% during the third quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company’s stock valued at $152,000 after purchasing an additional 3,740 shares during the last quarter. Wealth Effects LLC boosted its holdings in shares of Autolus Therapeutics by 19.5% in the 2nd quarter. Wealth Effects LLC now owns 49,000 shares of the company’s stock valued at $171,000 after buying an additional 8,000 shares during the last quarter. Bellevue Group AG grew its stake in shares of Autolus Therapeutics by 27.7% in the third quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock valued at $151,000 after buying an additional 9,000 shares in the last quarter. State Street Corp increased its holdings in Autolus Therapeutics by 1.7% during the third quarter. State Street Corp now owns 606,544 shares of the company’s stock worth $2,202,000 after buying an additional 10,401 shares during the last quarter. Finally, EntryPoint Capital LLC raised its position in Autolus Therapeutics by 113.6% during the first quarter. EntryPoint Capital LLC now owns 21,540 shares of the company’s stock worth $137,000 after acquiring an additional 11,456 shares in the last quarter. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.